Clinical aspects of sublingual immunotherapy tablets and drops

Tankersley, Mike; Han, Joseph K.; Nolte, Hendrik

doi:10.1016/j.anai.2019.12.025

Cited by 22 publications

(24 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLIT is considered safer than SCIT because no fatalities have been reported and the number of severe systemic reaction events is very low. The most common adverse effects of SLIT are mild local application site reactions, such as oral pruritus and throat irritation, which in the case of SLIT-T resolve within 30 to 60 min and decrease over time [22,30]. After administration of a sublingual tablet, anaphylactic shock occurs once every 100 million administrations, while after subcutaneous injection the incidence of anaphylaxis increases to one in 33,300 injections [7,15].…”

Section: Comparison Of Both Methodsmentioning

confidence: 99%

“…The medication use treatment effects were similar in the fourth comparison. However, it is not known whether the differences could arise from the dose [22].…”

Section: Comparison Of Both Methodsmentioning

confidence: 99%

“…By using SLIT drops, many allergens can be mixed, which increases the dosage variability of this drug [7]. Drops can be delivered via plastic single-use monodose squeeze vials, glass vials with droppers, metereddose pumps, or tuberculin syringes with the needle removed [22]. The stability of extracts is dependent on the diluent, temperature, and storage time.…”

Section: Sublingual Allergen-specific Immunotherapymentioning

confidence: 99%

“…The limited data imply that important inequalities in the formulation affect absorption and dissolution, which is related to clinical efficacy and safety. There were no SLIT-D products approved by the Food and Drug Administration (FDA) in the United States in 2020; therefore, there is no standard dosing formula for this mode of administration [22].…”

Section: Sublingual Allergen-specific Immunotherapymentioning

confidence: 99%

See 3 more Smart Citations

Sublingual and subcutaneous allergen-specific immunotherapy as a method of treatment of patients with inhalant allergy – a review of the literature

Pawlak¹,

Ręka²,

Korzeniowska³

et al. 2021

View full text Add to dashboard Cite

Allergy is the result of the body's intolerance to harmless antigens. In the treatment of respiratory allergies, allergen immunotherapy (AIT) is a causal method of treating allergies. It can be carried out via the subcutaneous route (SCIT) or the sublingual route (SLIT) -in the form of drops or tablets. Desensitisation is recommended from the age of 5 years, and the doses of the drug should be repeated gradually so that the body acquires immunological tolerance to allergens. Thirty-six current publications from the PubMed and Google Scholar platforms were reviewed. A series of studies confirming the safety, efficacy, and good tolerability of both types of AIT in children and adults were referred to. The results presented in the review show the similarities and differences between the desensitisation methods. They differ, among other things, in the convenience of use, the price, the frequency of side effects of treatment, and the dosage. StreszczenieAlergia jest skutkiem nietolerancji organizmu na nieszkodliwe antygeny. Immunoterapia alergenowa (AIT) jest metodą przyczynowego leczenia alergii układu oddechowego. Można ją stosować drogą podskórną (SCIT) lub podjęzykową (SLIT) -w postaci kropli lub tabletek. Odczulanie zalecane jest od 5. roku życia, a dawki leku należy powtarzać stopniowo, aby organizm nabył tolerancję immunologiczną na alergeny. W artykule dokonano przeglądu 36 aktualnych publikacji z platform PubMed i Google Scholar. W pracy odniesiono się do licznych badań potwierdzających bezpieczeństwo, skuteczność i dobrą tolerancję obu rodzajów AIT u dzieci i dorosłych. Wyniki przedstawione w przeglądzie ukazują podobieństwa i różnice między metodami odczulania. Obie metody różnią się między innymi wygodą stosowania, ceną, częstością występowania skutków ubocznych leczenia oraz dawkowaniem.

show abstract

Section: Comparison Of Both Methodsmentioning

confidence: 99%

“…The medication use treatment effects were similar in the fourth comparison. However, it is not known whether the differences could arise from the dose [22].…”

Section: Comparison Of Both Methodsmentioning

confidence: 99%

Section: Sublingual Allergen-specific Immunotherapymentioning

confidence: 99%

Section: Sublingual Allergen-specific Immunotherapymentioning

confidence: 99%

See 2 more Smart Citations

Sublingual and subcutaneous allergen-specific immunotherapy as a method of treatment of patients with inhalant allergy – a review of the literature

Pawlak¹,

Ręka²,

Korzeniowska³

et al. 2021

View full text Add to dashboard Cite

show abstract

“…antihistamine and intranasal corticosteroids), by allergen avoidance, or with allergy immunotherapy (AIT) 1,8 . AIT can be administered as subcutaneous immunotherapy (SCIT) or as sublingual immunotherapy (SLIT) (drops or tablets) 9 and is indicated for people who have AR that is not controlled by symptomatic therapy and who have confirmed IgE-mediated disease 6,10,11 . The long-term disease-modifying effect has been demonstrated after three to five years of AIT, due to the modification of the immunologic pathways causing the allergic response [12][13][14] .…”

Section: Introductionmentioning

confidence: 99%

Subcutaneous immunotherapy takes more than the time in the clinic

Tankersley

Winders

Aagren

et al. 2021

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

Objective: The aim of this study was to investigate the time use and both direct and indirect costs associated with subcutaneous immunotherapy (SCIT) for adults with allergic rhinitis (AR) and caregivers of children with AR in the US. Methods: We conducted a survey to assess the retrospective time use and direct costs of SCIT. The populations surveyed included adults and caregivers of children (aged 5-17) with symptomatic AR of moderate or higher severity who are currently receiving or have previously started allergy immunotherapy (AIT). The retrospectively collected, self-reported time consumption and direct costs per clinic visit when receiving SCIT were assessed as well as the productivity loss associated with SCIT. Data were analyzed using univariate descriptive statistics. Results: The study included 106 adults with AR and 191 caregivers of children with AR. We found that the median time spent per visit to the clinic was 50 min for both groups, including travel time and time at the clinic. The direct costs related to each visit included parking fees, road tolls and other costs.

show abstract

Preference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis

Bøgelund¹,

Rosado

Ruiz³

et al. 2022

Clinical & Translational All

View full text Add to dashboard Cite

Background This study investigated patients' preference for allergy immunotherapy (AIT) administered as either sublingual immunotherapy‐tablets versus monthly or weekly subcutaneous immunotherapy (SCIT) from a Spanish patient perspective. Methods A discrete choice experiment (DCE) consisting of two blocks with eight choice sets in each was constructed to elicit the preferences for AIT. Three attributes were included in the DCE for the mode of administration, including the frequency of administration, the risk of systemic reactions and the co‐payment. Adults and caregivers of children with moderate to severe allergic rhinitis (AR) were included if they were not currently receiving or had not previously received AIT. Results In total, 587 adults and 613 caregivers started the survey. Of those, 579 adults and 611 caregivers completed the survey and were included in the study. Both adults and caregivers had a significant preference for tablets compared with both monthly and weekly injections ( p ≤ 0.0001). Furthermore, the respondents showed a significant preference for reducing the risk of systemic reactions. Subgroup analyses showed that caregivers of polyallergic children and female caregivers were significantly less price sensitive when choosing their preferred treatment. Conclusion Our study demonstrated that both adults with AR and caregivers of children with AR prefer daily SLIT‐tablets to SCIT with either a weekly or monthly dose schedule.

show abstract

Clinical aspects of sublingual immunotherapy tablets and drops

Cited by 22 publications

References 93 publications

Sublingual and subcutaneous allergen-specific immunotherapy as a method of treatment of patients with inhalant allergy – a review of the literature

Sublingual and subcutaneous allergen-specific immunotherapy as a method of treatment of patients with inhalant allergy – a review of the literature

Subcutaneous immunotherapy takes more than the time in the clinic

Preference for sublingual immunotherapy with tablets in a Spanish population with allergic rhinitis

Contact Info

Product

Resources

About